Supply of Varilrix® and Priorix-Tetra® resumes
GSK recently identified a global manufacturing issue impacting some of our varicella- containing vaccines during routine quality testing. As a precautionary measure the release of all varicella-containing vaccines was put on hold which resulted in temporary disruptions to the supply of Varilrix® and Priorix-Tetra®.
GSK recently identified a global manufacturing issue impacting some of our varicella- containing vaccines during routine quality testing. As a precautionary measure the release of all varicella-containing vaccines was put on hold which resulted in temporary disruptions to the supply of Varilrix® and Priorix-Tetra®.
Following a thorough investigation and resolution of the issue, shipments will resume gradually by the end of February.
Corrective measures have been put in place at the manufacturing site to help prevent this issue from re-occurring.
Varilrix® is used to prevent chicken pox (Varicella) and Priorix-Tetra® for the prevention of chicken pox as well as measles, mumps and rubella.
GSK is committed to the ensuring the highest quality and supply of our medicines and vaccines to patients.
